Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEAM: Metformin and Fasting in Breast Cancer
NCT05023967Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of liquid metformin (Aspargo Labs) in breast cancer, ductal carcinoma in situ (DCIS), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2023; status: active, not recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
breast cancerductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NCT05023967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05023967.